Talis Biomedical Corp financial data

Location
Chicago, IL
Fiscal year end
31 December
Latest financial report
10-Q - Q2 2024 - 19 Aug 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 866% % -23%
Debt-to-equity 40% % 43%
Return On Equity -80% % -13%
Return On Assets -57% % -3.2%
Operating Margin -13510% % -327%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 31,686,494 shares 732%
Common Stock, Shares, Outstanding 1,822,153 shares 0.17%
Common Stock, Value, Issued $0 USD
Weighted Average Number of Shares Outstanding, Basic 1,822,422 shares 0.28%
Weighted Average Number of Shares Outstanding, Diluted 1,822,422 shares 0.28%

Income Statement

Label TTM Value / Value Unit Change %
Revenues $408,000 USD -86%
Research and Development Expense $20,477,000 USD -64%
Costs and Expenses $55,530,000 USD -40%
Operating Income (Loss) $55,122,000 USD 39%
Net Income (Loss) Attributable to Parent $51,026,000 USD 41%
Earnings Per Share, Basic -28 USD/shares 57%
Earnings Per Share, Diluted -28 USD/shares 57%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $59,867,000 USD -39%
Assets, Current $63,601,000 USD -38%
Property, Plant and Equipment, Net $425,000 USD -88%
Operating Lease, Right-of-Use Asset $7,907,000 USD -51%
Other Assets, Noncurrent $766,000 USD -50%
Assets $72,699,000 USD -41%
Accounts Payable, Current $3,790,000 USD 52%
Accrued Liabilities, Current $634,000 USD -32%
Liabilities, Current $8,196,000 USD -12%
Operating Lease, Liability, Noncurrent $15,877,000 USD -10%
Liabilities $24,073,000 USD -11%
Retained Earnings (Accumulated Deficit) $561,845,000 USD -10%
Stockholders' Equity Attributable to Parent $48,626,000 USD -49%
Liabilities and Equity $72,699,000 USD -41%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $6,427,000 USD 61%
Net Cash Provided by (Used in) Financing Activities $2,000 USD -94%
Net Cash Provided by (Used in) Investing Activities $30,000 USD
Common Stock, Shares Authorized 200,000,000 shares 0%
Common Stock, Shares, Issued 1,822,153 shares 0.17%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $6,395,000 USD 61%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $60,633,000 USD -40%
Operating Lease, Liability $18,800,000 USD -7.8%
Payments to Acquire Property, Plant, and Equipment $0 USD -100%
Lessee, Operating Lease, Liability, to be Paid $23,437,000 USD -11%
Operating Lease, Liability, Current $2,923,000 USD 6.8%
Lessee, Operating Lease, Liability, to be Paid, Year Two $3,144,000 USD 5.9%
Lessee, Operating Lease, Liability, to be Paid, Year One $3,055,000 USD 126%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $4,637,000 USD -21%
Lessee, Operating Lease, Liability, to be Paid, Year Three $3,235,000 USD 5.9%
Lessee, Operating Lease, Liability, to be Paid, Year Four $3,329,000 USD 5.9%
Share-based Payment Arrangement, Expense $3,484,000 USD -28%